This functional relationship positions NMB as a potential co-biomarker for RAS/RAF-mutated CRC cases, while simultaneously revealing novel opportunities to overcome MAPK inhibitor resistance through NMB-targeted intervention strategies. The gene discussed is NMB; the disease is colorectal carcinoma.